Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 16;159(2):77-85.
doi: 10.7326/0003-4819-159-2-201307160-00002.

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial

Nancy R Cook  1 , I-Min Lee, Shumin M Zhang, M Vinayaga Moorthy, Julie E Buring
Affiliations

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial

Nancy R Cook et al. Ann Intern Med. .

Abstract

Background: Recent evidence suggests that daily aspirin use decreases cancer risk, particularly for colorectal cancer, but evidence for alternate-day use is scant.

Objective: To examine the association between long-term, alternate-day, low-dose aspirin and cancer in healthy women.

Design: Observational follow-up of a randomized trial.

Setting: Female health professionals.

Participants: 39,876 women aged 45 years or older in the Women's Health Study (ClinicalTrials.gov: NCT00000479), 33 682 of whom continued observational follow-up.

Intervention: 100 mg of alternate-day aspirin or placebo through March 2004, with a median 10-year follow-up. Posttrial follow-up continued through March 2012.

Measurements: Cancer incidence.

Results: A total of 5071 cancer cases (including 2070 breast, 451 colorectal, and 431 lung cancer cases) and 1391 cancer deaths were confirmed. Over the entire follow-up, aspirin had no association with total (hazard ratio [HR], 0.97 [95% CI, 0.92 to 1.03]; P = 0.31), breast (HR, 0.98 [CI, 0.90 to 1.07]; P = 0.65), or lung (HR, 1.04 [CI, 0.86 to 1.26]; P = 0.67) cancer. Colorectal cancer was reduced in the aspirin group (HR, 0.80 [CI, 0.67 to 0.97]; P = 0.021), primarily for proximal colon cancer (HR, 0.73 [CI, 0.55 to 0.95]; P = 0.022). The difference emerged after 10 years, with a posttrial reduction of 42% (HR, 0.58 [CI, 0.42 to 0.80]; P < 0.001). There was no extended effect on cancer deaths or colorectal polyps. More gastrointestinal bleeding (HR, 1.14 [CI, 1.06 to 1.22]; P < 0.001) and peptic ulcers (HR, 1.17 [CI, 1.09 to 1.27]; P < 0.001) occurred in the aspirin group.

Limitations: Not all women received extended follow-up, and posttrial ascertainment bias cannot be ruled out. Gastrointestinal bleeding, peptic ulcers, and polyps were self-reported during extended follow-up.

Conclusion: Long-term use of alternate-day, low-dose aspirin may reduce risk for colorectal cancer in healthy women.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow of participants through the Women’s Health Study including extended follow-up.
Figure 2
Figure 2
Cumulative incidence of A) total, B) breast, C) colorectal, and D) lung cancer from time of randomization by randomized aspirin assignment, with p-value from log-rank test.
Figure 3
Figure 3
Post-trial incidence of colorectal cancer by randomized aspirin and post-trial aspirin use A) unweighted and B) weighted by inverse propensity of aspirin use post-trial.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

  • Aspirin in Primary Prevention: Looking for Those Who Enjoy It.
    Della Bona R, Giubilato S, Palmieri M, Benenati S, Rossini R, Di Fusco SA, Novarese F, Mascia G, Gasparetto N, Di Monaco A, Gatto L, Zilio F, Sorini Dini C, Borrello F, Geraci G, Riccio C, De Luca L, Colivicchi F, Grimaldi M, Giulizia MM, Porto I, Oliva FG. Della Bona R, et al. J Clin Med. 2024 Jul 16;13(14):4148. doi: 10.3390/jcm13144148. J Clin Med. 2024. PMID: 39064188 Free PMC article. Review.
  • Use of Nonsteroidal Anti-Inflammatory Drugs and Pancreatic Cancer Risk in the Women's Health Initiative.
    Brasky TM, Jager LR, Newton AM, Li X, Loomans-Kropp HA, Hays JL, Margolis KL, Luo J. Brasky TM, et al. Cancer Epidemiol Biomarkers Prev. 2024 Sep 3;33(9):1203-1210. doi: 10.1158/1055-9965.EPI-24-0305. Cancer Epidemiol Biomarkers Prev. 2024. PMID: 38900510
  • Two genome-wide interaction loci modify the association of nonsteroidal anti-inflammatory drugs with colorectal cancer.
    Drew DA, Kim AE, Lin Y, Qu C, Morrison J, Lewinger JP, Kawaguchi E, Wang J, Fu Y, Zemlianskaia N, Díez-Obrero V, Bien SA, Dimou N, Albanes D, Baurley JW, Wu AH, Buchanan DD, Potter JD, Prentice RL, Harlid S, Arndt V, Barry EL, Berndt SI, Bouras E, Brenner H, Budiarto A, Burnett-Hartman A, Campbell PT, Carreras-Torres R, Casey G, Chang-Claude J, Conti DV, Devall MAM, Figueiredo JC, Gruber SB, Gsur A, Gunter MJ, Harrison TA, Hidaka A, Hoffmeister M, Huyghe JR, Jenkins MA, Jordahl KM, Kundaje A, Le Marchand L, Li L, Lynch BM, Murphy N, Nassir R, Newcomb PA, Newton CC, Obón-Santacana M, Ogino S, Ose J, Pai RK, Palmer JR, Papadimitriou N, Pardamean B, Pellatt AJ, Peoples AR, Platz EA, Rennert G, Ruiz-Narvaez E, Sakoda LC, Scacheri PC, Schmit SL, Schoen RE, Stern MC, Su YR, Thomas DC, Tian Y, Tsilidis KK, Ulrich CM, Um CY, van Duijnhoven FJB, Van Guelpen B, White E, Hsu L, Moreno V, Peters U, Chan AT, Gauderman WJ. Drew DA, et al. Sci Adv. 2024 May 31;10(22):eadk3121. doi: 10.1126/sciadv.adk3121. Epub 2024 May 29. Sci Adv. 2024. PMID: 38809988 Free PMC article.
  • Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.
    Petrucci G, Buck GA, Rocca B, Parish S, Baigent C, Hatem D, Mafham M, Habib A, Bowman L, Armitage J, Patrono C. Petrucci G, et al. Eur Heart J. 2024 Apr 14;45(15):1355-1367. doi: 10.1093/eurheartj/ehad868. Eur Heart J. 2024. PMID: 38385506 Free PMC article.
  • Human cytomegalovirus infection enhances 5‑lipoxygenase and cycloxygenase‑2 expression in colorectal cancer.
    Pantalone MR, Martin Almazan N, Lattanzio R, Taher C, De Fabritiis S, Valentinuzzi S, Bishehsari F, Mahdavinia M, Verginelli F, Rahbar A, Mariani-Costantini R, Söderberg-Naucler C. Pantalone MR, et al. Int J Oncol. 2023 Nov;63(5):116. doi: 10.3892/ijo.2023.5564. Epub 2023 Sep 1. Int J Oncol. 2023. PMID: 37654195 Free PMC article.
See all "Cited by" articles

References

    1. Chan AT, Arber N, Burn J, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Phila) 2012;5(2):164–78. - PMC - PubMed
    1. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol. 2009;10(5):501–7. - PubMed
    1. Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol. 2012;23(6):1403–15. - PubMed
    1. Cole BF, Logan RF, Halabi S, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66. - PMC - PubMed
    1. Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet. 2010;376(9754):1741–50. - PubMed

Publication types

MeSH terms

Associated data